Philip M. Boffey
Phil Boffey is former deputy editor of the New York Times Editorial Board and editorial page writer, primarily focusing on the impacts of science and health on society. He was also editor of Science Times and a member of two teams that won Pulitzer Prizes.
Neuroscience Confronts RacismNeuroethics Viewpoint
The Black Lives Matter protests have triggered an intense bout of soul-searching and frantic efforts to erase all vestiges of racism from institutions around the nation, including neuroscience.
Jumping the GunNeuroethics Viewpoint
While the mobilization of the world’s scientific community to understand Covid-19 is unprecedented in history, keep in mind that more than 4,000 papers—known as preprints—have yet to be peer-reviewed.
Troubling Regulatory StandardsNeuroethics Viewpoint
Our neuroethics columnist addresses a concerning new trend of reporting brain research results through the popular media rather than in peer reviewed journals.
The Social Media ConundrumNeuroethics Viewpoint
What can be done to overcome the devious tactics used by tech companies to ensnare teens in compulsively using and returning to social media?
Do Violent Video Games Lead to Violence?Neuroethics Viewpoint
Violent video games of every shape and form are all the rage in the marketplace, but the jury is still out on their link to real-world aggression. Column by Philip M. Boffey.
INS Keynote Address: Martha Farah on the Impact of SESReport from the International Neuroethics Society Conference, 2019
Martha J. Farah delivered a spirited defense of the fledgling field of neuroethics to a supportive audience on Friday, the final day of the 2019 annual meeting of the International Neuroethics Society (INS), in Chicago.
Guns and the Mental Health MisnomerNeuroethics Viewpoint
While mass shootings continue to escalate, politics has led to the absence of solid, peer-reviewed research that will help identify individuals who might commit violent crimes. Column by Philip M. Boffey
The Marijuana DebateNeuroethics Viewpoint
There has been a huge increase in legalization and use of cannabis (marijuana) in recent years. Each step raises ethical issues for health care providers, patients, and government officials.
Pfizer’s Alzheimer’s Drug DecisionNeuroethics Viewpoint
Is a pharmaceutical giant morally obligated to spend $80 million on a clinical trial when its research suggests that a new drug may hold the promise to treat Alzheimer’s disease?
Minding the Brain MachinesNeuroethics Viewpoint
The outcome of a lawsuit against the makers of Prevagen could have profound consequences for the ability of authorities to regulate advertising on supplements. Neuroethics column for Brain in the News.